CYP2C9 and rheumatoid arthritis: Although the CPIC does not recommend routine screening for CYP2C9 and CYP2C8 non-functional alleles before ibuprofen therapy, a comprehensive understanding of these genetic variations can assist in optimizing ibuprofen dosage and reducing the risk of ADRs in RA patients.